|
|
|
|
All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin. Our model showed that apixaban was the most effective anticoagulant in a general atrial fibrillation population and has an incremental cost-effectiveness rate >$50000/QALY. For those with higher stroke risk (CHADS>3), dabigatran was the most cost-effective treatment option. |
|